Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata

Franssen, A.M.H.W.; Willemsen, Wim N.P.; Corbey, R.S.; Doesburg, W.H.; Veen, A. J. van ’t; Rolland, R.

doi:10.1016/0028-2243(91)90121-z

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small numbers of patients will experience a localized allergic reaction at the sight of injection of depot formulations of GnRH agonists. In some cases, hyaline degeneration of the myoma and bone loss has been reported [21, 80,81,82,83]. The above symptoms are poorly tolerated and, hence, GnRH agonist therapy without add-back therapy is limited to the time before surgery.…”

Section: Side Effects Of Gnrh Agonist Administrationmentioning

confidence: 98%

Role of GnRH agonists prior to endoscopic surgical treatment of fibroids

Theodoridis

Tarlatzis

Bontis

2005

Eur Clinics Obstet Gynecol

View full text Add to dashboard Cite

Uterine fibroids are the most common benign tumors found in women of reproductive age and their treatment is mainly by surgery, especially if they are symptomatic. Since the boom in endoscopy, many reports conclude that treatment of fibroids can be performed safely by laparoscopy or hysteroscopy.The development of GnRH analogues is not only a breakthrough in the field of obstetrics and gynecology, but a major leap forward in the treatment of various hormone-dependent diseases in general medicine. Recently GnRH agonistic analogues have been applied to treat various gynecological conditions, such as uterine leiomyomas, endometriosis, dysfunctional uterine bleeding, hyperandrogenism (polycystic ovaries) and infertility, cancer and precocious puberty.GnRH agonist administration prior to the surgical approach to uterine fibroids has a positive role in the management of these tumors, because-despite the expense-they reduce fibroid and uterine volume and intraoperative blood loss and they increase hemoglobin levels prior to surgical intervention. GnRH agonists can be used preoperatively in the field of endoscopic surgery in selected cases, especially in hysteroscopic surgery. However, their exact role in the laparoscopic management of fibroids needs further evaluation.

show abstract

Section: Side Effects Of Gnrh Agonist Administrationmentioning

confidence: 98%

Role of GnRH agonists prior to endoscopic surgical treatment of fibroids

Theodoridis

Tarlatzis

Bontis

2005

Eur Clinics Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…Most investigators observed a significant reduction of uterine volume during therapy with various agonists by different delivery sys tems. With regard to posttreatment follow-up, few au thors reported a persistent reduction in the majority of patients, but most of the recent publications describe the regrowth of myomas once therapy was stopped [3][4][5][6][7], Also preoperative agonist treatment is used to facilitate the surgery and to reduce postoperative morbidity, but this approach may increase a risk that at the time of sur gery small myomas could be nonrecognizable because of the reduced uterine volume [8].…”

Section: Introductionmentioning

confidence: 99%

Postoperative GnRH Analog Treatment for the Prevention of Recurrences of Uterine Myomas after Myomectomy

Vavala

Lanzone²,

Monaco³

et al. 1997

Gynecol Obstet Invest

View full text Add to dashboard Cite

Sixty-five patients with uterine myomas were studied after surgery to investigate the effect of periodic GnRH analog treatment on the prevention of recurrences. A group of patients was treated by leuprolide acetate depot 3 months a year for 3 years. At the end of treatment, these patients showed a significantly reduced uterine volume and myoma recurrence rate as compared to untreated patients. A role of GnRH analogs in the clinical prevention of myoma recurrence could be suggested.

show abstract